A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
46actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-06 | actual | When the study began enrolling |
| Primary completion | 2025-08-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-25 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatic Insufficiency
- Healthy
Intervention
- Drug: Olomorasib — also filed as LY3537982
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Maximum observed concentration (Cmax) of Olomorasib
measured Predose on Day 1 up to 96 hours postdose
PK: Area under the concentration versus time curve from time zero to infinity (AUC0-inf) of Olomorasib
measured Predose on Day 1 up to 96 hours postdose
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed